Table 3.
IL-37 (pg/ml) | VEGF (pg/ml) | Ang-2 (pg/ml) | |
---|---|---|---|
Stage I | 81.01±25.49 | 137.233±49.02 | 239.42±65.07 |
Stage II | 67.64±33.97 | 210.15±50.14 | 612.79±135.68 |
Stage III | 30.70±17.90 | 357.83±70.45 | 966.04±374.83 |
P value | <0.01 | <0.01 | <0.01 |
IL-37 (pg/ml) | VEGF (pg/ml) | Ang-2 (pg/ml) | |
---|---|---|---|
Stage I | 81.01±25.49 | 137.233±49.02 | 239.42±65.07 |
Stage II | 67.64±33.97 | 210.15±50.14 | 612.79±135.68 |
Stage III | 30.70±17.90 | 357.83±70.45 | 966.04±374.83 |
P value | <0.01 | <0.01 | <0.01 |